Decentralized Trials and Research Alliance: new members Firma Clinical, MMS Holdings

10-Feb-2021 - Last updated on 10-Feb-2021 at 14:40 GMT

The Decentralized Trials and Research Alliance has welcomed Firma Clinical and MMS Holdings to its membership roster. The group, launched in late 2020, aims to bring together various stakeholders to build awareness of, increase access to, and advance technologies in decentralized studies.

Michael Woods, Firma Clinical CEO, said, “As a company that has been a leader in patient centricity, Firma is pleased to be a member of DTRA and join this important initiative to advance decentralized research and make the clinical trial process more patient focused while increasing trial efficiency.”

Eric Harvey, MMS’s director of biostatics and data science, said, “As a specialized data services and technologies provider, MMS will help guide the life sciences industry into an exciting future where decentralized trials and research help the world find treatments and cures at a more rapid pace.”